HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced it will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A detailed press release will be issued prior to the call. This announcement matters because it signals HeartBeam's continued advancement toward commercializing its innovative 3D ECG technology, which could significantly impact how cardiac conditions are detected and monitored outside traditional clinical settings.
HeartBeam is developing the first cable-free device capable of collecting ECG signals in three dimensions, from three non-coplanar directions, and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care, all outside a medical facility. This redefines the future of cardiac health management by enabling earlier detection and continuous monitoring of heart conditions, potentially reducing hospital visits and improving patient outcomes.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, a critical milestone. The 12-Lead ECG synthesis software is currently under FDA review. Additionally, HeartBeam holds over 20 issued patents related to technology enablement, protecting its intellectual property and competitive position. The upcoming conference call will provide investors and stakeholders with insights into the company's regulatory progress, including any updates on the FDA review, and commercial-readiness activities. These updates are crucial for understanding HeartBeam's path to market and potential impact on the cardiac monitoring market.
For more information, the full press release is available at this link. The latest news and updates relating to BEAT can be found in the company's newsroom at this page. HeartBeam's technology addresses a significant need in cardiac care, where timely detection of issues like arrhythmias or heart attacks can be life-saving. By enabling remote monitoring and diagnosis, HeartBeam could reduce healthcare costs and improve access to care, particularly for patients in rural or underserved areas.
The conference call will be a key event for investors to gauge the company's progress and future direction. As HeartBeam moves toward commercial launch, the implications of its technology extend beyond business metrics; they encompass potential improvements in patient care and healthcare efficiency. The company's focus on regulatory and commercial milestones indicates a strategic approach to bringing its product to market, which could position it as a leader in the cardiac monitoring space.
